CDC34 suppresses macrophage phagocytic activity and predicts poor response to immune checkpoint inhibitor in cancers
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217822 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Xiao-Liang Jie und 20 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Molecular Oncology & Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hosp…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Phagocytosis, Macrophages, Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Chinese Academy of Medical Sciences Initiative for Innovative Medicine, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
The Cell Division Cycle 34 (CDC34) is an E2 ubiquitin-conjugating enzyme that is required for proteasomal degradation of substrate proteins, and is able to stabilize proteins including the epidermal growth factor receptor to promote lung carcinogenesis. Here, we conducted a pan-cancer analysis of CDC34 in The Cancer Genome Atlas datasets, and found its high expression in breast cancer and negative association with patient outcomes. Analysis of single-cell RNA-sequencing data revealed a negative role of CDC34 in macrophage phagocytotic activity for cancer cells. CDC34 stabilized hypoxia-inducible factor 1α (HIF1α) and transcriptionally upregulated CD47 in cancer cells to evade phagocytosis by macrophages. Inhibition of CDC34 inhibited tumor growth and synergized with anti-PD-L1 antibody in murine models. CDC34 was positively associated with CD47 and negatively associated with CD8+ granzyme B+ T-cell infiltration in patient samples, and patients with co-overexpression of CDC34 and CD47 had markedly poorer prognosis compared to those with high expression of either marker alone. In pre-treatment tumor samples, non-responders to immunotherapy exhibited significantly higher CDC34 levels and reduced CD8+ T-cell infiltration compared to responders. These findings indicated that CDC34 is critical to immune evasion and could be a potential therapeutic target for those resistant to immune checkpoint inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Molecular Oncology & Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Col…
- Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
- Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250117, Shandong, China.
- Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
- Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
- Department of Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Förderung
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Jie, X. L., Wei, J. C., Wang, D., Zhang, X. W., Lv, M. Y., Lin, Y. F., Tan, Y. S., Wang, Z., Alifu, A., Ji, L., Shen, Y. K., Wang, C., Xu, B. Q., Liu, Z., Han, S. C., Wang, Z. H., Tong, X. W., Feng, L., Ying, J. M., …, & Wang, G. Z. (2025). CDC34 suppresses macrophage phagocytic activity and predicts poor response to immune checkpoint inhibitor in cancers. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217822
Vancouver
Jie XL, Wei JC, Wang D, Zhang XW, Lv MY, Lin YF, et al. CDC34 suppresses macrophage phagocytic activity and predicts poor response to immune checkpoint inhibitor in cancers. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217822
BibTeX
@article{Jie2025,
author = {Jie, Xiao-Liang and Wei, Jia-Cong and Wang, Di and Zhang, Xiang-Wei and Lv, Meng-Yao and Lin, Yong-Fang and Tan, Yi-Shuai and Wang, Zheng and Alifu, Aikede and Ji, Lei and Shen, Yu-Ke and Wang, Cong and Xu, Bing-Qing and Liu, Zheng and Han, Si-Chong and Wang, Zi-Hao and Tong, Xiao-Wan and Feng, Lin and Ying, Jian-Ming and Zhou, Guang-Biao and Wang, Gui-Zhen},
title = {CDC34 suppresses macrophage phagocytic activity and predicts poor response to immune checkpoint inhibitor in cancers},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217822}
}
EUVIMED